Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

People with alopecia areata often have lower vitamin D levels, which may be linked to the condition's severity.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Tofacitinib effectively treats Alopecia Areata.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

People with alopecia areata often have low vitamin D levels, which may worsen their hair loss.

The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.